These findings should not be used as an excuse not to optimize renin–angiotensin system inhibition and target urinary protein in patients with proteinuric nephropathies. Figure 1: Rate of GFR ...

Given the few therapeutic options available for proteinuric nephropathies and the antiproteinuric effects of endothelin-receptor antagonists when given at low doses, future nephrology research may ...

The case indicates that bromadiolone can lead to acute kidney injury (AKI) due to a severe and prolonged coagulation disorder ...

Phytate (Myo-inositol hexaphosphate) is the main phosphorus storage system in plant seeds such as those of cereal grains, nuts, oilseeds, and legumes (Raboy, 2000; Reddy et al., 1982), accounting for ...

Mutations in the COL4A3, COL4A4, or COL4A5 genes that prevent the normal assembly of a345(IV) collagen in the glomerular basement membrane (GBM) cause a spectrum of nephropathies with diverse clinical ...

Uric acid nephropathies have been observed in nongouty family members. In view of the high incidence of hyperuricemia in the diabetic population an increased risk of nephropathy might, then ...

Kidney transplantation (KTx) represents the best choice among the available therapies for End Stage Renal Disease (ESRD) patients. However, the long-term survival of a functioning kidney graft still ...

The data support that inhibition of PKR and mitochondrial dysfunction has potential clinical significance for HIVAN. We hypothesized that PKR activation is a mechanistic pathway shared by HIV- and ...

Fourteen patients were monitored as follow-up. Thirty-one patients with other nephropathies and 20 healthy volunteers were included as controls. Results In SLE, urinary CD4 T cell counts ≥800/100 ml ...

The underlying conditions included Crohn’s Disease (n = 262, 31%), rheumatoid arthritis (n = 133, 16%), ulcerative colitis (n = 118, 14%), spondyloarthropathies (n = 86, 10%), psoriatic arthritis (n = ...

Inhibition of tumor angiogenesis is a universal approach for the treatment of tumors. This calls for the development of more effective next-generation anti-angiogenic drugs for advancing the ...

Summary: The LITESPARK-005 phase 3 clinical enrolled 746 patients with metastatic clear cell renal cell carcinoma (ccRCC) who had progressed after treatment with both an immune checkpoint ...